Product Description
for the treatment of endothelial dysfunction in patients with diabetes mellitus; An 50% ethanolic extract of Lindera obtusiloba stems (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01836172)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Han Wha Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Diabetes Complications
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HW2012-YJP002 | P2 |
Unknown status |
Diabetes Complications |
2016-12-01 |